Illinois, Deerfield Launch Alma Therapeutics
The University of Illinois Urbana-Champaign and healthcare investment firm Deerfield Management have formed a translational research partnership named Alma Therapeutics.
Updated on Nov. 3, 2026 in Biotech
Live Poll
Do you trust private firms partnering with universities to put patients ahead of profits?
The University of Illinois Urbana-Champaign and Deerfield Management launched Alma Therapeutics on November 2, 2026, a collaboration to move Illinois laboratory discoveries toward therapeutic programs. Alma will be housed in the Carl R. Woese Institute for Genomic Biology.
Why it matters
The partnership pairs university research with an investment firm's scientific and financial experience to help translate discoveries into drugs. It is intended to open drug discovery across disciplines at institutes and departments throughout the University of Illinois system.
The announced commitment is a possible 10-year funding term from Deerfield, with no dollar figure disclosed. The total amount and the programs it will support remain unspecified.
The players
University of Illinois Urbana-Champaign
A public research university in Champaign, Illinois, and a major center for biological and chemical research.
Deerfield Management
A healthcare-focused investment firm that invests in biotechnology and therapeutic development companies.
The details
Alma Therapeutics will work with Illinois faculty, beginning this fall, to evaluate translational research and expedite next-generation therapeutics across campus. The partnership builds on Deerfield's 2024 investment in Excelsior Sciences, a company co-founded by Illinois chemistry professor Martin D. Burke.
Timeline
2024: Deerfield invests in Excelsior Sciences.
November 2, 2026: Alma Therapeutics partnership launches.
Fall 2026: Alma begins evaluating Illinois faculty translational research.
Next 10 years: Deerfield may provide substantial funding.
Big Picture
Alma sits inside the Carl R. Woese Institute for Genomic Biology, extending that institute's research toward drug development through a private investment partner.
For Champaign residents and University of Illinois researchers, the partnership creates a new channel for faculty discoveries to move toward clinical programs. Patients may eventually benefit if those programs reach the market, though no timeline for any therapy has been announced.
The takeaway
Academic discoveries often stall before reaching patients, and dedicated translational partnerships like Alma aim to close that gap. Readers tracking Illinois biotech should watch whether the promised funding and faculty evaluations produce named therapeutic programs.
Further reading
Explore more Biotech developments from the Champaign research community.
Source note: This article includes information reported by Pantagraph.
Live Poll
Do you trust private firms partnering with universities to put patients ahead of profits?
